{"id":"W3200056356","doi":"10.1055/a-1647-9896","title":"Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study","year":2021,"lang":"en","type":"article","venue":"Thrombosis and Haemostasis","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Cilag; LEO Pharma; Ipsen; Pfizer; Vifor Pharma; Amgen; ZonMw; Daiichi Sankyo Europe; Bayer HealthCare; Sanofi; Servier; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Apixaban; Regimen; Hazard ratio; Pulmonary embolism; Randomized controlled trial; Surgery; Clinical endpoint; Venous thrombosis; Internal medicine; Thrombosis; Confidence interval; Warfarin; Atrial fibrillation; Rivaroxaban","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0409525,0.002504019,0.005516984,0.000949578,0.001470758,0.003136633,0.002360176,0.003619871,0.005159175],"category_scores_gemma":[0.02195895,0.001628365,0.003277407,0.001500087,0.003408095,0.001912861,0.001710357,0.005406813,0.002179552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001183582,"about_ca_system_score_gemma":0.004712736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004062281,"about_ca_topic_score_gemma":0.0007583817,"domain_scores_codex":[0.9747733,0.01890358,0.002069374,0.001551451,0.001954642,0.0007476903],"domain_scores_gemma":[0.9924347,0.002441827,0.001304626,0.001205513,0.001044528,0.001568815],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.7755002,0.02804198,0.01864775,0.01184541,0.004606596,0.0007893846,0.0009263591,0.003617312,0.008941721,0.02165509,0.01329307,0.1121351],"study_design_scores_gemma":[0.7571915,0.1530766,0.009302158,0.002178912,0.003588342,0.0005837658,0.0001797099,0.004367355,0.001820784,0.008908452,0.05860757,0.0001947814],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.2463192,0.07140772,0.04940443,0.0157382,0.01032928,0.5714412,0.007571669,0.0003981854,0.02739002],"genre_scores_gemma":[0.3999192,0.01869256,0.06218204,0.01273167,0.005544218,0.4948924,0.002820976,0.0001025541,0.003114328],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.0409525,"threshold_uncertainty_score":0.2165802,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05993991657109114,"score_gpt":0.3034428731773453,"score_spread":0.2435029566062542,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}